Retrospective Evaluation of Minimally-Invasive Surgical Strategies in Ovarian Neoplasms (REMISSION Study)
This observational study aims to evaluate the outcomes of patients with early-stage epithelial ovarian cancer who are treated with minimally invasive surgery (such as laparoscopic or robotic surgery). Specifically, the study will look at: 1. Post-Surgery Complications * What is the rate of complications within 30 days after surgery? * How often do patients require readmission to the hospital, re-operation, or conversion to open surgery? 2. Cancer Outcomes * What is the rate of cancer upstaging (when the cancer spreads to a more advanced stage during surgery for example because of an intra-operative ovarian cyst rupture)? * What are the overall survival and disease-free survival rates for patients treated with minimally invasive surgery? Researchers will compare two groups of patients: Group 1: Patients with early-stage ovarian cancer treated with minimally invasive surgery. Group 2: Patients with early-stage ovarian cancer treated with open surgery. The goal is to see if there are any differences in post-surgery complications, recovery, and cancer outcomes between the two groups. Fertility-Sparing Treatment: The study will also compare patients who are undergoing fertility-sparing treatments for early-stage ovarian cancer. Two subgroups will be looked at: * Patients receiving fertility-sparing surgery through a minimally invasive procedure. * Patients receiving fertility-sparing surgery through an open surgery. The same outcomes (complications, survival, etc.) will be assessed and compared between these two groups as well.
• Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation
• Patients who underwent surgery between January 2014 and December 2023
• Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure
• Patients with final pathology report of Epithelial Ovarian Cancer